Logo

Mankind Pharma Share Price

NSE: MANKIND
|
Pharmaceuticals
₹ 2,528.60
+₹41.70 (1.68%)
1D
Last updated 03 Jul, 2026, 15:58 IST

Mankind Pharma Share Price Today

As of 5 Jul 2026, Mankind Pharma share price is ₹2,528.60. The stock opened at ₹2,498.90, compared to its previous close of ₹2,486.90. During today's trading session, Mankind Pharma share price moved in the range of ₹2,480.20 to ₹2,543.00, with an average price of ₹2,511.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,909.70 and a high of ₹2,716.50. On the performance front, Mankind Pharma share price has increased by 14.80% over the last six months and is up 7.07% on a year-on-year basis.

₹2,480.20
1.68% up today
₹2,543.00
1D LOW
1D HIGH

Mankind Pharma Returns Calculator

Open
₹2,498.90
High
₹2,543.00
Low
₹2,480.20
Prev. close
₹2,486.90
Circuit
L
H
₹2,275.80
₹2,781.40
52-week
L
H
₹1,909.70
₹2,716.50

Mankind Pharma Shareholder Returns

Mankind Pharma Share Price History

Mkt Cap Cr
1,02,729.00
P/E
53.00
P/B
6.30
ROE
11.74%
D/E
0.34
ROCE
13.13%
Div. Yield
0.04%
EPS(TTM)
49.37
Turnover
0.54
EV/EBITDA
28.17
Net Margin
0.00%
Op. Margin
0.00%
ROA
6.90%
Quick Ratio
0.00
Curr. Ratio
1.72
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Mankind Pharma outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Mankind Pharma appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Mankind Pharma earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72
Biocon68,267.90185.351.991.14%0.043.64%168.190.12%0.090.27

Mankind Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹12,207.44₹10,260.44₹8,749.43₹7,781.56
Other Income₹536.79₹280.22₹128.57₹196.03
Total Revenue₹12,744.23₹10,540.66₹8,878.00₹7,977.58
Total Expenses₹10,240.14₹8,157.93₹7,219.18₹6,017.43
Profit Before Tax₹2,516.33₹2,397.94₹1,671.24₹1,974.60
Tax₹509.74₹457.15₹361.56₹521.64
Profit After Tax₹2,006.59₹1,940.79₹1,309.68₹1,452.96
EPS - Basic₹49.28₹47.75₹32.00₹35.78
EPS - Diluted₹49.20₹47.68₹32.00₹35.78

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹2,524.78₹2,399.35₹1,671.24₹1,974.60
Income before WC changes₹3,126.55₹2,611.54₹1,969.67₹2,005.41
Change in Assets-₹441.39-₹226.35₹222.73-₹1,234.85
Change in Liabilities₹294.97₹208.78-₹56.00₹648.73
Change in WC-₹146.42-₹17.57₹166.73-₹586.12
Cash flow from Operations₹2,413.38₹2,152.44₹1,813.30₹919.78
Cash flow from Investing-₹12,682.95-₹2,081.69-₹1,054.13-₹1,369.14
Cash flow from Financing₹10,232.56₹5.27-₹739.73₹604.62
Total Cash Flow-₹37.01₹76.02₹19.44₹155.26
Cash (Start of the year)₹382.01₹304.82₹283.06₹127.33
Cash (End of the year)₹403.88₹382.01₹304.82₹283.06

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹20,771.26₹5,395.03₹5,387.58₹4,740.92
Current Assets₹6,988.27₹6,568.22₹4,327.87₹4,406.82
Total Assets₹27,759.53₹11,963.25₹9,715.45₹9,147.74
Current Liabilities₹5,663.56₹2,119.73₹1,863.14₹2,623.46
Net Current Asset₹1,324.71₹4,448.49₹2,464.74₹1,783.35
Non-Current Liabilities₹7,527.79₹267.73₹229.02₹207.96
Equity Capital₹14,568.18₹9,575.79₹7,623.29₹6,316.31
Total Equity & Liabilities₹27,759.53₹11,963.25₹9,715.45₹9,147.74

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹9,497.80₹8,629.25₹8,127.15₹7,486.22
Other Income₹493.21₹270.50₹162.78₹203.81
Total Revenue₹9,991.01₹8,899.75₹8,289.94₹7,690.04
Total Expenses₹7,685.02₹6,714.55₹6,727.10₹5,818.60
Profit Before Tax₹2,305.99₹2,185.20₹1,562.84₹1,871.44
Tax₹421.74₹412.57₹314.58₹482.01
Profit After Tax₹1,884.25₹1,772.63₹1,248.26₹1,389.42
EPS - Basic₹48.16₹46.84₹31.16₹34.68
EPS - Diluted₹48.07₹46.77₹31.16₹34.68

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹2,390.36₹2,325.72₹1,562.84₹1,871.44
Income before WC changes₹2,729.71₹2,490.46₹1,789.84₹1,867.28
Change in Assets-₹233.68-₹583.75₹427.77-₹1,149.71
Change in Liabilities₹297.61₹250.37-₹133.55₹564.09
Change in WC₹63.93-₹333.38₹294.21-₹585.61
Cash flow from Operations₹2,322.16₹1,736.08₹1,798.99₹821.44
Cash flow from Investing-₹12,114.68-₹1,665.19-₹1,040.61-₹1,360.27
Cash flow from Financing₹9,845.34-₹4.73-₹710.41₹578.63
Total Cash Flow₹52.82₹66.16₹47.96₹39.81
Cash (Start of the year)₹211.62₹145.46₹86.17₹46.36
Cash (End of the year)₹200.29₹211.62₹134.13₹86.17

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹19,132.31₹5,886.84₹5,854.21₹5,122.99
Current Assets₹4,696.01₹5,629.55₹3,516.91₹3,815.71
Total Assets₹23,828.32₹11,516.39₹9,371.12₹8,938.70
Current Liabilities₹4,091.52₹1,616.56₹1,419.09₹2,271.27
Net Current Asset₹604.49₹4,012.99₹2,097.82₹1,544.44
Non-Current Liabilities₹5,096.53₹197.06₹168.12₹126.98
Equity Capital₹14,640.27₹9,702.77₹7,783.91₹6,540.45
Total Equity & Liabilities₹23,828.32₹11,516.39₹9,371.12₹8,938.70
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
2528.6
20
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 20
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
60.79
Neutral
ATR (14)
69.74
Neutral
STOCH(9,6)
62.28
Neutral
STOCH RSI (14)
61.91
Neutral
ADX(9)
36.48
Bearish
UO(9)
42.35
Neutral
ROC(12)
7.32
Bullish
WillR(14)
-28.64
Neutral
Period
Simple value
Exponential vaue
5D
2507.48
2504.85
10D
2496.38
2485.72
20D
2434.25
2454.78
50D
2401.32
2383.99
100D
2248.62
2318.58

About Mankind Pharma

Mankind Pharma logo
ISIN
INE634S01028
Sector Market Cap
₹ 1,02,729 Cr

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Mankind Pharma Financial Highlights

  • Revenue: Mankind Pharma reported revenue of ₹14,636.43 crore in FY26 vs ₹12,744.23 crore in FY25. It showed an increase of 14.85% on a yearly basis.
  • Operating Profit: Mankind Pharma reported an operating profit of ₹2,332.68 crore in FY26 vs ₹2,516.33 crore in FY25. It showed a decrease of 7.30% on a year-on-year basis.
  • Net Profit: Mankind Pharma reported a net profit of ₹1,938.10 crore in FY26 vs ₹2,011.12 crore in FY25. It showed a decrease of 3.63% on a yearly basis.

Mankind Pharma Quarterly Result Highlights

  • Mankind Pharma reported revenue of ₹3,557.22 crore in Mar 2026, compared with ₹3,639.95 crore in Dec 2025, representing a decrease of 2.27% on a quarter-on-quarter (QoQ) basis.
  • Mankind Pharma reported an operating profit of ₹659.17 crore in Mar 2026, compared with ₹509.00 crore in Dec 2025, representing an increase of 29.50% on a quarter-on-quarter (QoQ) basis.
  • Mankind Pharma reported a profit of ₹559.42 crore in Mar 2026, compared with ₹413.88 crore in Dec 2025, reflecting an increase of 35.16% on a QoQ basis.
  • The earnings per share (EPS) of Mankind Pharma stood at ₹49.28 during Mar 2026.
Know more
Promoters
72.66%
FII
10.24%
Other DII
4.10%
Retail and other
2.64%
Mutual funds
10.36%
Foreign institutions - FII
Compare against other stocks
Mankind Pharma logo
Mankind Pharma
Pharmaceuticals
Add Stock
Add Another

FAQs on Mankind Pharma Share Price